Overview

Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC

Status:
NOT_YET_RECRUITING

Trial end date:
2030-11-01

Target enrollment:

Participant gender:

Summary

Study to evaluate the efficacy and safety of the combination of Atezolizumab and Bevacizumab as neoadjuvant plus adjuvant treatment in Hepatocellular Carcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

Fundacion Clinic per a la Recerca Biomdica

Treatments:

atezolizumab
Bevacizumab